Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.65 |
| ▸ | GLP1R | P43220 | 3/20 | 0.63 |
| ▸ | GCGR | P47871 | 1/20 | 0.63 |
| ▸ | GIPR | P48546 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.58 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31182903 | 0.95 | TFPI (0.65) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL30277897 | 0.95 | TFPI (0.60) | TFPIGLP1RGCGRGIPRRXFP1 | |
| Misgurin SCHEMBL29509599 | 0.93 | TFPI (0.72) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL30607324 | 0.93 | VIPR1 (0.65) | GLP1RGCGRGIPRRXFP1PTH1R | |
| SCHEMBL31678895 | 0.93 | TFPI (0.60) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL29949376 | 0.92 | GLP1R (0.63) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL30194463 | 0.92 | TFPI (0.66) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL30658242 | 0.92 | TFPI (0.66) | TFPIGLP1RGCGRGIPRRXFP1 | |
| SCHEMBL30432173 | 0.92 | VIPR1 (0.69) | TFPIGLP1RGCGRGIPRPTH1R | |
| SCHEMBL29551264 | 0.92 | TFPI (0.71) | TFPIGLP1RPTH1RVIPR1ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-10 | — | — | US | disclosed |
| EP-4122926-B1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO (JP) | 2025-06-04 | — | — | EP | disclosed |
| CN-119818502-A | Pharmaceutical composition containing triazine derivative | 盐野义制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025074997-A1 | CONDENSED HETEROCYCLIC DERIVATIVE HAVING VIRAL PROLIFERATION INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2025-04-10 | — | — | WO | disclosed |
| US-20250099474-A1 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | SHIONOGI & CO., LTD. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-20250092056-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4506342-A1 | URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi & Co., Ltd (JP) | 2025-02-12 | — | — | EP | disclosed |
| US-20250025459-A1 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | SHIONOGI & CO., LTD. (JP) | 2025-01-23 | — | — | US | disclosed |
| WO-2023054732-A2 | PHARMACEUTICAL FOR TREATING NOVEL CORONAVIRUS INFECTION | 塩野義製薬株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054292-A1 | PHARMACEUTICAL COMPOSITION CONTAINING TRIAZINE DERIVATIVE | 塩野義製薬株式会社 | 2023-04-06 | — | — | WO | disclosed |
| CN-115850249-A | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023042879-A1 | BICYCLIC HETEROCYCLIC DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2023-03-23 | — | — | WO | disclosed |
| WO-2023033098-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING VIRUS GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2023-03-09 | — | — | WO | disclosed |
| WO-2023027198-A1 | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVE | 塩野義製薬株式会社 | 2023-03-02 | — | — | WO | disclosed |
| EP-4122926-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi & Co., Ltd (JP) | 2023-01-25 | — | — | EP | disclosed |
| CN-115038696-A | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022138987-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022138988-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099474-A1 | PHARMACEUTICAL FOR TREATMENT OF NOVEL CORONAVIRUS INFECTION | ACE, ACE2, TMPRSS2 | TFPI 31/4885GLP1R 2160/4885GCGR 2888/4885 |
| US-20250092056-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE, SARS1, RNASEL | TFPI 864/4885GLP1R 1031/4885GCGR 2495/4885 |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | NSUN2, ZC3HAV1, IFNAR1 | TFPI 4220/4885GLP1R 2151/4885GCGR 1493/4885 |
| US-20250025459-A1 | COVID-19 TREATMENT MEDICINE CHARACTERIZED BY COMBINING 3CL PROTEASE INHIBITOR AND COVID-19 TREATMENT DRUG | ACE, ACE2, TMPRSS2 | TFPI 142/4885GLP1R 188/4885GCGR 1012/4885 |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SARS1, ACE, ACE2 | TFPI 801/4885GLP1R 2773/4885GCGR 3970/4885 |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE2, ACE, SARS1 | TFPI 1168/4885GLP1R 1472/4885GCGR 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.